Sex-Biased Molecular Signature for Overall Survival of Liver Cancer Patients

  • Kim, Sun Young (Department of Chemistry, College of Natural Sciences, Duksung Women's University) ;
  • Song, Hye Kyung (Department of Chemistry, College of Natural Sciences, Duksung Women's University) ;
  • Lee, Suk Kyeong (Department of Medical Life Sciences, Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea) ;
  • Kim, Sang Geon (College of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University_Seoul) ;
  • Woo, Hyun Goo (Department of Physiology, Ajou University School of Medicine) ;
  • Yang, Jieun (Department of Physiology, Ajou University School of Medicine) ;
  • Noh, Hyun-Jin (Department of Biomedical Science, Graduate School, Ajou University) ;
  • Kim, You-Sun (Department of Biomedical Science, Graduate School, Ajou University) ;
  • Moon, Aree (Duksung Innovative Drug Center, College of Pharmacy, Duksung Women's University)
  • Received : 2020.09.09
  • Accepted : 2020.09.18
  • Published : 2020.11.01


Sex/gender disparity has been shown in the incidence and prognosis of many types of diseases, probably due to differences in genes, physiological conditions such as hormones, and lifestyle between the sexes. The mortality and survival rates of many cancers, especially liver cancer, differ between men and women. Due to the pronounced sex/gender disparity, considering sex/gender may be necessary for the diagnosis and treatment of liver cancer. By analyzing research articles through a PubMed literature search, the present review identified 12 genes which showed practical relevance to cancer and sex disparities. Among the 12 sex-specific genes, 7 genes (BAP1, CTNNB1, FOXA1, GSTO1, GSTP1, IL6, and SRPK1) showed sex-biased function in liver cancer. Here we summarized previous findings of cancer molecular signature including our own analysis, and showed that sex-biased molecular signature CTNNB1High, IL6High, RHOAHigh and GLIPR1Low may serve as a female-specific index for prediction and evaluation of OS in liver cancer patients. This review suggests a potential implication of sex-biased molecular signature in liver cancer, providing a useful information on diagnosis and prediction of disease progression based on gender.



  1. Addis, R., Campesi, I., Fois, M., Capobianco, G., Dessole, S., Fenu, G., Montella, A., Cattaneo, M. G., Vicentini, L. M. and Franconi, F. (2014) Human umbilical endothelial cells (HUVECs) have a sex: characterisation of the phenotype of male and female cells. Biol. Sex Differ. 5, 18.
  2. Allahyar, A. and de Ridder, J. (2015) FERAL: network-based classifier with application to breast cancer outcome prediction. Bioinformatics 31, i311-i319.
  3. Awasthi, A., Woolley, A. G., Lecomte, F. J., Hung, N., Baguley, B. C., Wilbanks, S. M., Jeffs, A. R. and Tyndall, J. D. (2013) Variable expression of GLIPR1 correlates with invasive potential in melanoma cells. Front. Oncol. 3, 225.
  4. Babaei, S., Hulsman, M., Reinders, M. and de Ridder, J. (2013) Detecting recurrent gene mutation in interaction network context using multi-scale graph diffusion. BMC Bioinformatics 14, 29.
  5. Barker, N. (2008) The canonical Wnt/beta-catenin signalling pathway. Methods Mol. Biol. 468, 5-15.
  6. Behari, J. (2010) The Wnt/$\beta$-catenin signaling pathway in liver biology and disease. Expert Rev. Gastroenterol. Hepatol. 4, 745-756.
  7. Bellizzi, A., Mangia, A., Chiriatti, A., Petroni, S., Quaranta, M., Schittulli, F., Malfettone, A., Cardone, R. A., Paradiso, A. and Reshkin, S. J. (2008) RhoA protein expression in primary breast cancers and matched lymphocytes is associated with progression of the disease. Int. J. Mol. Med. 22, 25-31.
  8. Bianchi, I., Lleo, A., Gershwin, M. E., and Invernizzi, P. (2012) The X chromosome and immune associated genes. J. Autoimmun. 38, J187-J192.
  9. Borras, C., Sastre, J., Garcia-Sala, D., Lloret, A., Pallardo, F. V. and Vina, J. (2003) Mitochondria from females exhibit higher antioxidant gene expression and lower oxidative damage than males. Free Radic. Biol. Med. 34, 546-552.
  10. Bottarelli, L., Azzoni, C., Necchi, F., Lagrasta, C., Tamburini, E., D'Adda, T., Pizzi, S., Sarli, L., Rindi, G. and Bordi, C. (2007) Sex chromosome alterations associate with tumor progression in sporadic colorectal carcinomas. Clin. Cancer Res. 13, 4365-4370.
  11. Bovelstad, H. M., Nygard, S., Storvold, H. L., Aldrin, M., Borgan, O., Frigessi, A. and Lingjaerde, O. C. (2007) Predicting survival from microarray data-a comparative study. Bioinformatics 23, 2080-2087.
  12. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. and Jemal, A. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394-424.
  13. Budhu, A., Jia, H. L., Forgues, M., Liu, C., Goldstein, D., Lam, A., Zanetti, K. A., Ye, Q., Qin, L., Croce, C. M., Tang, Z. and Wang, X. W. (2008) Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47, 897-907.
  14. Cantuti-Castelvetri, I., Keller-McGandy, C., Bouzou, B., Asteris, G., Clark, T. W., Frosch, M. P. and Standaert, D. G. (2007) Effects of gender on nigral gene expression and parkinson disease. Neurobiol. Dis. 26, 606-614.
  15. Clayton, J. A. and Tannenbaum, C. (2016) Reporting sex, gender, or both in clinical research? JAMA 316, 1863-1864.
  16. Cohen, A. L., Soldi, R., Zhang, H., Gustafson, A. M., Wilcox, R., Welm, B. E., Chang, J. T., Johnson, E., Spira, A., Jeffrey, S. S. and Bild, A. H. (2011) A pharmacogenomic method for individualized prediction of drug sensitivity. Mol. Syst. Biol. 7, 513.
  17. Cook, M. B., Dawsey, S. M., Freedman, N. D., Inskip, P. D., Wichner, S. M., Quraishi, S. M., Devesa, S. S. and McGlynn, K. A. (2009) Sex disparities in cancer incidence by period and age. Cancer Epidemiol. Biomarkers Prev. 18, 1174-1182.
  18. De Rienzo, A., Archer, M. A., Yeap, B. Y., Dao, N., Sciaranghella, D., Sideris, A. C., Zheng, Y., Holman, A. G., Wang, Y. E., Dal Cin, P. S. Fletcher, J. A., Rubio, R., Croft, L., Quackenbush, J., Sugarbaker, P. E., Munir, K. J., Battilana, J, R., Gustafson, C. E., Chirieac, L. R., Ching, S. M., Wong, J., Tay, L. C., Rudd, S., Hercus, R., Sugarbaker, D. J., Richards, W. J. and Bueno, R. (2016) Gender-specific molecular and clinical features underlie malignant pleural mesothelioma. Cancer Res. 76, 319-328.
  19. El-Maarri, O., Becker. T., Junen, J., Manzoor, S. S., Diaz-Lacava, A., Schwaab, R., Wienker, T. and Oldenburg, J. (2007) Gender specific differences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher methylation levels in males. Hum. Genet. 122, 505-514.
  20. Erstad, D. J., Fuchs, B. C. and Tanabe, K. K. (2018) Molecular signatures in hepatocellular carcinoma: a step toward rationally designed cancer therapy. Cancer 124, 3084-3104.
  21. Evanson, J. R., Guyton, M. K., Oliver, D. L., Hire, J. M., Topolski, R. L., Zumbrun, S. D., McPherson, J. C. and Bojescul, J. A. (2014) Gender and age differences in growth factor concentrations from platelet-rich plasma in adults. Mil. Med. 179, 799-805.
  22. Fish, E. N. (2008) The X-files in immunity: sex-based differences predispose immune responses. Nat. Rev. Immunol. 8, 737-744.
  23. Gabriele, L., Buoncervello, M., Ascione, B., Bellenghi, M., Matarrese, P. and Care, A. (2016) The gender perspective in cancer research and therapy: novel insights and on-going hypotheses. Ann. Ist. Super. Sanita 52, 213-222.
  24. Garcia-Herreros, M., Aparicio, I. M., Rath, D., Fair, T. and Lonergan, P. (2012) Differential glycolytic and glycogenogenic transduction pathways in male and female bovine embryos produced in vitro. Reprod. Fertil. Dev. 24, 344-352.
  25. Ghuwalewala, S., Ghatak, D., Das, P., Dey, S., Sarkar, S., Alam, N., Panda, C. K. and Roychoudhury, S. (2016) CD44(high)CD24(low) molecular signature determines the Cancer Stem Cell and EMT phenotype in Oral Squamous Cell Carcinoma. Stem Cell Res. 16, 405-417.
  26. Gleicher, N. and Barad, D. H. (2007) Gender as risk factor for autoimmune diseases. J. Autoimmun. 28, 1-6.
  27. Graveley, B. R. (2000) Sorting out the complexity of SR protein functions. RNA 6, 1197-1211.
  28. Guy, J. and Peters, M. G. (2013) Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes. Gastroenterol. Hepatol. 10, 633-639.
  29. Haley, W. E., Roth, D. L., Howard, G. and Safford, M. M. (2010) Caregiving strain and estimated risk for stroke and coronary heart disease among spouse caregivers: differential effects by race and sex. Stroke 41, 331-336.
  30. Hanahan, D. and Weinberg, R. A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674.
  31. Harish, G., Venkateshappa, C., Mahadevan, A., Pruthi, N., Bharath, M. M. and Shankar, S. K. (2013) Mitochondrial function in human brains is affected by pre- and post mortem factors. Neuropathol. Appl. Neurobiol. 39, 298-315.
  32. Heasman, S. J. and Ridley, A. J. (2008) Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat. Rev. Mol. Cell Biol. 9, 690-701.
  33. Heidari, S., Babor, T. F., De Castro, P., Tort, S. and Curno, M. (2016) Sex and gender equity in research: rationale for the SAGER guidelines and recommended use. Res. Integr. Peer Rev. 1, 2.
  34. Hines, A., Staff, F. J., Widdows, J., Compton, R. M., Falciani, F. and Viant, M. R. (2010) Discovery of metabolic signatures for predicting whole organism toxicology. Toxicol. Sci. 115, 369-378.
  35. Hou, J., Xu, J., Jiang, R., Wang, Y., Chen, C., Deng, L., Huang, X., Wang, X., and Sun, B. (2013) Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. Hepatology 57, 678-688.
  36. Hur, J., Sullivan, K. A., Pande, M., Hong, Y., Sima, A. A. F., Jagadish, H. V., Kretzler, M. and Feldman, E. L. (2011) The identification of gene expression profiles associated with progression of human diabetic neuropathy. Brain 134, 3222-3235.
  37. Ippolito, J. E., Yim, A. K., Luo, J., Chinnaiyan, P. and Rubin, J. B. (2017) Sexual dimorphism in glioma glycolysis underlies sex differences in survival. JCI Insight 2, e92142.
  38. Jiao, Y., Li, Y., Jiang, P., Han, W. and Liu, Y. (2019) PGM5: a novel diagnostic and prognostic biomarker for liver cancer. PeerJ 7, e7070.
  39. Jung, K. W., Won, Y. J., Kong, H. J. and Lee, E. S. (2019) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2016. Cancer Res. Treat. 51, 417-430.
  40. Klein, S. L. and Flanagan, K. L. (2016) Sex differences in immune responses. Nat. Rev. Immunol. 16, 626-638.
  41. Klinge, C. M. (2012) miRNAs and estrogen action. Trends Endocrinol. Metab. 23, 223-233.
  42. Kohi, M. P. (2016) Gender-related differences in hepatocellular carcinoma: does sex matter? J. Vasc. Interv. Radiol. 27, 1338-1341.
  43. Kouzmenko, A. P., Takeyama, K., Ito, S., Furutani, T., Sawatsubashi, S., Maki, A., Suzuki, E., Kawasaki, Y., Akiyama, T., Tabata, T. and Kato, T. (2004) Wnt/beta-catenin and estrogen signaling converge in vivo. J. Biol. Chem. 279, 40255-40258.
  44. Krumsiek, J., Mittelstrass, K., Do, K. T., Stuckler, F., Ried, J., Adamski, J., Peters, A., Illig, T., Kronenberg, F., Friedrich, N., Nauck, M., Pietzner, M., Mook-Kanamori, D. O., Suhre, K., Gieger, C., Grallert, H., Theis, F. J. and Kastenmuller, G. (2015) Gender-specific pathway differences in the human serum metabolome. Metabolomics 11, 1815-1833.
  45. Kumari, N., Dwarakanath, B. S., Das, A. and Bhatt, A. N. (2016) Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 37, 11553-11572.
  46. Laffont, S., Blanquart, E. and Guery, J. C. (2017) Sex differences in asthma: a key role of androgen-signaling in group 2 innate lymphoid cells. Front. Immunol. 8, 1069.
  47. Li, C. H., Haider, S., Shiah, Y. J., Thai, K. and Boutros, P. C. (2018) Sex differences in cancer driver genes and biomarkers. Cancer Res. 78, 5527-5537.
  48. Li, L., Ren, C., Yang, G., Fattah, E. A., Goltsov, A. A., Kim, S. M., Lee, J. S., Park, S., Demayo, F. J., Ittmann, M. M., Troncoso, P. and Thompson, T. C. (2011) GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. Cancer Res. 71, 7694-7704.
  49. Li, Y., Kang, K., Krahn, J. M., Croutwater, N., Lee, K., Umbach, D. M. and Li, L. (2017) A comprehensive genomic pan-cancer classification using The Cancer Genome Atlas gene expression data. BMC Genomics 18, 508.
  50. Li, Z., Tuteja, G., Schug, J. and Kaestner, K. H. (2012) Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell 148, 72-83.
  51. Libert, C., Dejager, L., and Pinheiro, I. (2010) The X chromosome in immune functions: when a chromosome makes the difference. Nat. Rev. Immunol. 10, 594-604
  52. Lin, C. W., Lin, C. C., Mo, L. R., Chang, C. Y., Perng, D. S., Hsu, C. C., Lo, G. H., Chen, Y. S., Yen, Y. C., Hu, J. T., Yu, M. L., Lee, P. H., Lin, J. T. and Yang, S. S. (2013) Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. J. Hepatol. 58, 730-735.
  53. Liu, F., Yuan, J. H., Huang, J. F., Yang, F., Wang, T. T., Ma, J. Z., Zhang, L., Zhou, C. C., Wang, F., Yu, J., Zhou, W. P. and Sun, S. H. (2016) Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding MCM2 and miR-374a. Oncogene 35, 5422-5434.
  54. Liu, W. C. and Liu, Q. Y. (2014) Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma. World J. Gastroenterol. 20, 6252-6261.
  55. Masoomian, B., Shields, J. A. and Shields, C. L. (2018) Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma. J. Curr. Ophthalmol. 30, 102-109.
  56. Mehrabian, M., Allayee, H., Stockton, J., Lum, P. Y. , Drake, T. A., Castellani, L. W., Suh, M., Armour, C., Edwards, S., Lamb, J., Lusis, A. J. and Schadt, E. E. (2007) Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits. Nat. Genet. 37, 1224-1233.
  57. Mervic, L. (2012) Time course and pattern of metastasis of cutaneous melanoma differ between men and women. PLoS ONE 7, e32955.
  58. Mittelstrass, K., Ried, J. S., Yu, Z., Krumsiek, J., Gieger, C., Prehn, C., Roemisch-Margl, W., Polonikov, A., Peters, A., Theis, F. J., Meitinger, T., Kronenberg, F., Weidinger, S., Wichmann, H. E., Suhre, K., Wang-Sattler, R., Adamski, J. and Illig, T. (2011) Discovery of sexual dimorphisms in metabolic and genetic biomarkers. PLoS Genet. 7, e1002215.
  59. Mosley, M., Weathington, J., Cortes, L. R., Bruggeman, E., Castillo-Ruiz, A., Xue, B. and Forger, N. G. (2017) Neonatal inhibition of DNA methylation alters cell phenotype in sexually dimorphic regions of the mouse brain. Endocrinology 158, 1838-1848.
  60. Mulligan, M. A., Wegner, K. A., Keil, K. P., Mehta, V., Taketo, M. M. and Vezina, C. M. (2017) Beta-catenin and estrogen signaling collaborate to drive cyclin D1 expression in developing mouse prostate. Differentiation 93, 66-71.
  61. Murphy, E. V., Zhang, Y., Zhu, W. and Biggs, J. (1995) The human glioma pathogenesis-related protein is structurally related to plant pathogenesis-related proteins and its gene is expressed specifically in brain tumors. Gene 159, 131-135.
  62. Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M. and Karin, M. (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317, 121-124.
  63. Niu, D., Zhang, J., Ren, Y., Feng, H. and Chen, W. N. (2009) HBx genotype D represses GSTP1 expression and increases the oxidative level and apoptosis in HepG2 cells. Mol. Oncol. 3, 67-76.
  64. Nilsson, R., Bjorkegren, J. and Tegner, J. (2009) On reliable discovery of molecular signatures. BMC Bioinformatics 10, 38.
  65. Nugent, B. M., Wright, C. L., Shetty, A. C., Hodes, G. E., Lenz, K. M., Mahurkar, A., Russo, S. J., Devine, S. E. and McCarthy, M. M. (2015) Brain feminization requires active repression of masculinization via DNA methylation. Nat. Neurosci. 18, 690-697.
  66. Pal, S. K. and Hurria, A. (2010) Impact of age, sex, and comorbidity on cancer therapy and disease progression. J. Clin. Oncol. 28, 4086-4093.
  67. Pelletier, R., Khan, N. A., Cox, J., Daskalopoulou, S. S., Eisenberg, M. J., Bacon, S. L., Lavoie, K. L., Daskupta, K., Rabi, D., Humphries, K. H., Norris, C. M., Thanassoulis, G., Behlouli, H. and Pilote, L.; GENESIS-PRAXY Investigators (2016) Sex versus gender-related characteristics: which predicts outcome after acute coronary syndrome in the young? J. Am. Coll. Cardiol. 67, 127-135.
  68. Pinheiro, I., Dejager, L. and Libert, C. (2011) X-chromosome-located microRNAs in immunity: might they explain male/female differences? The X chromosome-genomic context may affect X-located miRNAs and downstream signaling, thereby contributing to the enhanced immune response of females. Bioessays 33, 791-802.
  69. Pittman, J., Huang, E., Dressman, H., Horng, C. F., Cheng, S. H., Tsou, M., Chen, C., Bild, A., Iversen, E. S., Huang, A. T., Nevins, J. R. and West, M. (2004) Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc. Natl. Acad. Sci. U.S.A. 101, 8431-8436.
  70. Qiu, J., Peng, B., Tang, Y., Qian, Y., Guo, P., Li, M., Luo, J., Chen, B., Tang, H., Lu, C., Cai, M., Ke, Z., He, W., Zheng, Y., Xie, D., Li, B. and Yuan, Y. (2017) CpG methylation signature predicts recurrence in early-stage hepatocellular carcinoma: results from a multicenter study. J. Clin. Oncol. 35, 734-742.
  71. Qu, K., Liu, S. S., Wang, Z. X., Huang, Z. C., Liu, S. N., Chang, H. L., Xu, X. S., Lin, T., Dong, Y. F. and Liu, C. (2015) Polymorphisms of glutathione S-transferase genes and survival of resected hepatocellular carcinoma patients. World J. Gastroenterol. 21, 4310-4322.
  72. Rahbari, R., Zhang L. and Kebebew, E. (2010) Thyroid cancer gender disparity. Future Oncol. 6, 1771-1779.
  73. Rebouissou, S., Franconi, A., Calderaro, J., Letouze, E., Imbeaud, S., Pilati, C., Nault, J. C., Couchy, G., Laurent, A., Balabaud, C., Bioulac-Sage, P. and Zucman-Rossi, J. (2016) Genotype-phenotype correlation of CTNNB1 mutations reveals different ${\beta}$-catenin activity associated with liver tumor progression. Hepatology 64, 2047-2061.
  74. Reizel, Y., Spiro, A., Sabag, O., Skversky, Y., Hecht, M., Keshet, I., Berman, B. P. and Cedar, H. (2015) Gender-specific postnatal demethylation and establishment of epigenetic memory. Genes Dev. 29, 923-933.
  75. Ren, C., Li, L., Yang, G., Timme, T. L., Goltsov, A., Ren, C., Ji, X., Addai, J., Luo, H., Ittmann, M. M. and Thompson, T. C. (2004) RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res. 64, 969-976.
  76. Rich, N. E., Murphy, C. C., Yopp, A. C., Tiro, J., Marrero, J. A. and Singal, A. G. (2020) Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma. Aliment. Pharmacol. Ther. 52, 701-709.
  77. Rubin, J. B., Lagas, J. S., Broestl, L., Sponagel, J., Rockwell, N., Rhee, G., Rosen, S. F., Chen, S., Klein, R. S., Imoukhuede, P. and Luo, J. (2020) Sex differences in cancer mechanisms. Biol. Sex Differ. 11, 17.
  78. Sailland, J., Tribollet, V., Forcet, C., Billon, C., Barenton, B., Carnesecchi, J., Bachmann, A., Gauthier, K. C., Yu, S., Giguere, V., Chan, F. L. and Vanacker, J. (2014) Estrogen-related receptor $\alpha$ decreases RHOA stability to induce orientated cell migration. Proc. Natl. Acad. Sci. U.S.A. 111, 15108-15113.
  79. Salehi, S., Jafarian, A. H., Montazer, M., Moghbeli, M. and Forghanifard, M. M. (2017) BRUCE protein, new marker for targeted therapy of gastric carcinoma. J. Gastrointest. Cancer 48, 151-155.
  80. Scosyrev, E., Noyes, K., Feng, C. and Messing, E. (2009) Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 115, 68-74,
  81. Scotland, R. S., Stables, M. J., Madalli, S., Watson, P. and Gilroy, D. W. (2011) Sex differences in resident immune cell phenotype underlie more efficient acute inflammatory responses in female mice. Blood 118, 5918-5927.
  82. Setiawan, V. W., Lim, U., Lipworth, L., Lu, S. C., Shepherd, J., Ernst, T., Wilkens, L. R., Henderson, B. E. and Le Marchand, L. (2016) Sex and ethnic differences in the association of obesity with risk of hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 14, 309-316.
  83. Shin, J. Y., Jung, H. J. and Moon, A. (2019) Molecular markers in sex differences in cancer. Toxicol. Res. 35, 331-341.
  84. Shirasaki, F., Takata, M., Hatta, N. and Takehara, K. (2001) Loss of expression of the metastasis suppressor gene KiSS1 during melanoma progression and its association with LOH of chromosome 6q16.3-q23. Cancer Res. 61, 7422-7425.
  85. Skavdahl, M., Steenbergen, C., Clark, J., Myers, P., Demianenko, T., Mao, L., Rockman, H. A., Korach, K. S. and Murphy, E. (2005) Estrogen receptor-beta mediates male-female differences in the development of pressure overload hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 288, 469-476.
  86. Smalley, K. S. (2018) Why do women with melanoma do better than men? Elife 7, e33511.
  87. Smyth, E. C., Fassan, M., Cunningham, D., Allum, W. H., Okines, A. F. C., Lampis, A., Hahne, J. C., Rugge, M., Peckitt, C., Nankivell, M., Langley, R., Ghidini, M., Braconi, C., Wotherspoon, A., Grabsch, H. I. and Valeri, N. (2016) Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial. J. Clin. Oncol. 34, 2721-2727.
  88. Smyth, E. C., Nyamundanda, G., Cunningham, D., Fontana, E., Ragulan, C., Tan, I. B., Lin, S. J., Wotherspoon, A., Nankivell, M., Fassan, M., Lampis, A., Hahne, J. C., Davies, A. R., Lagergren, J., Gossage, J. A., Maisey, N., Green, M., Zylstra, J. L., Allum, W. H., Langley, R. E., Tan, P., Valeri, N. and Sadanandam, A. (2018) A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. Ann. Oncol. 29, 2356-2362.
  89. Snell, D. M. and Turner, J. M. A. (2018) Sex chromosome effects on male-female differences in mammals. Curr. Biol. 28, R1313-R1324.
  90. So, A. R., Si, J. M., Lopez, D. and Pellegrini, M. (2020) Molecular signatures for inflammation vary across cancer types and correlate significantly with tumor stage, sex and vital status of patients. PLoS ONE 15, e0221545.
  91. Spatz, A., Borg, C. and Feunteun, J. (2004) X-chromosome genetics and human cancer. Nat. Rev. Cancer 4, 617-629.
  92. Stein, B. and Yang, M. X. (1995) Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol. Cell. Biol. 15, 4971-4979.
  93. Sung, J., Wang, Y., Chandrasekaran, S., Witten, D. M. and Price, N. D. (2012) Molecular signatures from omics data: from chaos to consensus. Biotechnol. J. 7, 946-957.
  94. Tang, H., Wang, S., Xiao, G., Schiller, J., Papadimitrakopoulou, V., Minna, J., Wistuba, I. and Xie, Y. (2017) Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies. Ann. Oncol. 28, 733-740.
  95. Tobi, E. W., Lumey, L. H., Talens, R. P., Kremer, D., Putter, H., Stein, A. D., Slagboom, P. E. and Heijmans, B. T. (2009) DNA methylation differences after exposure to prenatal famine are common and timing- and sex-specific. Hum. Mol. Genet. 18, 4046-4053.
  96. van de Vijver, M. J., He, Y. D., van't Veer, L. J., Dai, H., Hart, A. A., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., Parrish, M., Atsma, D., Witteveen, A., Glas, A., Delahaye, L., van der Velde, T., Bartelink, H., Rodenhuis, S., Rutgers, E. T., Friend, S. H. and Bernards, R. (2002) A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009.
  97. Villa, E., Critelli, R., Lei, B., Marzocchi, G., Camma, C., Giannelli, G., Pontisso, P., Cabibbo, G., Enea, M., Colopi, S., Caporali, C., Pollicino, T., Milosa, F., Karampatou, A., Todesca, P., Bertolini, E., Maccio, L., Martinez-Chantar, M. L., Turola, E., Del Buono, M., De Maria, N., Ballestri, S., Schepis, F., Loria, P., Gerunda, G. E., Losi, L. and Cillo, U. (2016) Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut 65, 861-869.
  98. Wang, R., Ye, X. H., Zhao, X. L., Liu, J. L. and Zhang, C. Y. (2019) Development of a five-gene signature as a novel prognostic marker in ovarian cancer. Neoplasma 66, 343-349.
  99. Wang, Y., Xing, T., Huang, L., Song, G., Sun, X., Zhong, L., Fan, J., Yan, D., Zhou, C., Cui, F., Yu, F., Chen, J., Yu, Y., Li, C., Tang, H., Peng, Z. and Wang, X. (2015) Period 1 and estrogen receptor-beta are downregulated in Chinese colon cancers. Int. J. Clin. Exp. Pathol. 8, 8178-8188.
  100. Welzel, T. M., Graubard, B. I., Quraishi, S., Zeuzem, S., Davila, J. A., El-Serag, H. B. and McGlynn, K. A. (2013) Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am. J. Gastroenterol. 108, 1314-1321.
  101. Wijchers, P. J. and Festenstein, R. J. (2011) Epigenetic regulation of autosomal gene expression by sex chromosomes. Trends Genet. 27, 132-140.
  102. Wu, E. M., Wong, L. L., Hernandez, B. Y., Ji, J. F., Jia, W., Kwee, S. A. and Kalathil, S. (2018) Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. Hepatoma Res. 4, 66.
  103. Wu, Y., Yao, N., Feng, Y., Tian, Z., Yang, Y. and Zhao, Y. (2019) Identification and characterization of sexual dimorphism-linked gene expression profile in hepatocellular carcinoma. Oncol. Rep. 42, 937-952.
  104. Xia, J., Urabe, K., Moroi, Y., Koga, T., Duan, H., Li, Y. and Furue, M. (2006) beta-Catenin mutation and its nuclear localization are confirmed to be frequent causes of Wnt signaling pathway activation in pilomatricomas. J. Dermatol. Sci. 41, 67-75.
  105. Xie, L., Xie, L., Kinnings, S. L. and Bourne, P. E. (2012) Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu. Rev. Pharmacol. Toxicol. 52, 361-379.
  106. Xiong, G., Lingampalli, N., Koltsov, J. C. B., Leung, L. L., Bhutani, N., Robinson, W. H. and Chu, C. R. (2018) Men and women differ in the biochemical composition of platelet-rich plasma. Am. J. Sports Med. 46, 409-419.
  107. Xu, G., Zhang, M., Zhu, H. and Xu, J. (2017) A 15-gene signature for prediction of colon cancer recurrence and prognosis based on SVM. Gene 604, 33-40.
  108. Xu, J., Deng, X., Watkins, R. and Disteche, C. M. (2008) Sex-specific differences in expression of histone demethylases Utx and Uty in mouse brain and neurons. J. Neurosci. 28, 4521-4527.
  109. Yaron, M., Renner, U., Gilad, S., Stalla, G. K., Stern, N. and Greenman, Y. (2015) KISS1 receptor is preferentially expressed in clinically non-functioning pituitary tumors. Pituitary 18, 306-311.
  110. Yu, L., Liu, X., Wang, X., Dang, Z., Jiang, Y., Wang, X. and Yang, Z. (2019) Impact of gender as a prognostic factor in HBV-related hepatocellular carcinoma: the survival strength of female patients in BCLC stage 0-B. J. Cancer 10, 4237-4244.
  111. Yuasa, Y. (2010) Epigenetics in molecular epidemiology of cancer a new scope. Adv. Genet. 71, 211-235.
  112. Zhang, J., Jiang, H., Xia, W., Jiang, Y., Tan, X., Liu, P., Jia, H., Yang, X. and Shen, G. (2016) Serine-arginine protein kinase 1 is associated with hepatocellular carcinoma progression and poor patient survival. Tumour Biol. 37, 283-290.
  113. Zhang, L. J., Xiong, Y., Nilubol, N., He, M., Bommareddi, S., Zhu, X., Jia, L., Xiao, Z., Park, J. W., Xu, X., Patel, D., Willingham, M. C., Cheng, S. Y. and Kebebew, E. (2015) Testosterone regulates thyroid cancer progression by modifying tumor suppressor genes and tumor immunity. Carcinogenesis 36, 420-428.
  114. Zhao, L., Jiang, L., He, L., Wei, Q., Bi, J., Wang Y., Yu, L., He, M., Zhao, L. and Wei, M. (2019) Identification of a novel cell cycle-related gene signature predicting survival in patients with gastric cancer. J. Cell. Physiol. 234, 6350-6360.